Related Experiment Videos
Dinitrochlorobenzene therapy in alopecia areata.
A Kalam1, M D Tahseen, S F Islam
1Department of Medicine (Skin and Venereal Diseases), JN Medical College, Aligarh Muslim University.
Journal of the Indian Medical Association
|January 1, 1991
Summary
Topical dinitrochlorobenzene (DNCB) therapy effectively promoted hair regrowth in 72% of alopecia areata patients within 3-6 months. However, 10% experienced severe side effects, necessitating treatment cessation.
Area of Science:
- Dermatology
- Immunology
Background:
- Alopecia areata is an autoimmune condition causing hair loss.
- Current treatments have varying efficacy and side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of topical dinitrochlorobenzene (DNCB) for treating alopecia areata.
Main Methods:
- Topical dinitrochlorobenzene (DNCB) therapy was administered to 50 patients with alopecia areata.
- Hair regrowth and adverse events were monitored over 3 to 6 months.
Main Results:
- Hair regrowth was observed in 36 (72%) patients.
- Five patients (10%) developed severe contact dermatitis and vesiculation, requiring treatment discontinuation.
- No response was noted in 7 patients (14%), and 4 (8%) experienced other side effects.
Conclusions:
- Topical DNCB is a potentially effective treatment for alopecia areata, inducing hair regrowth in a majority of patients.
- Careful monitoring is essential due to the risk of significant adverse reactions like severe contact dermatitis.